FDA scientists say evidence is insufficient to support compounding seven popular peptide therapies backed by Health Secretary Robert F. Kennedy Jr. An advisory panel with some peptide-industry ties will review the products in July.
FDA scientists say evidence is insufficient to support compounding seven popular peptide therapies backed by Health Secretary Robert F. Kennedy Jr. An advisory panel with some peptide-industry ties will review the products in July.